Monoclonal antibodies as a treatment for Lassa virus

Recruiting

• Conditions: Lassa Virus Infection; viral hemorrhagic fever; 10047438

• Registration Number: NL-OMON53355
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 26 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 5

Inclusion Criteria

- Written informed consent to store samples and perform genetic testing.
- Age >= 18 years
- Individuals who have experienced PCR proven LASV infection and minimally 4
weeks post-infection

Exclusion Criteria

- Mental disorder that in the view of the investigator would interfere with
adherence to the treatment or the study procedures, or the decision to
participate in the study.
- Immunosuppressive medication or other diseases associated with
immunodeficiency.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Neutralization potency and breadth of monoclonal antibodies derived from LASV<br /><br>individuals who have recovered from LASV infection as assayed in neutralization<br /><br>assays using lentiviral vectors pseudo-typed with Lassa GP protein </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Percentage Lassa GP positive memory B cells as assayed by FACS (clonality)<br /><br>using Lassa GP protein labelled in different colors<br /><br>- Sequence screening of the most promising LASV monoclonal antibodies</p><br>